Predicted to enable transmembrane transporter activity. Predicted to be involved in several processes, including sodium-dependent phosphate transport; urate metabolic process; and urate transport. Predicted to be located in apical plasma membrane. Orthologous to human SLC17A1 (solute carrier family 17 member 1); INTERACTS WITH 1-naphthyl isothiocyanate; 2,3,7,8-tetrachlorodibenzodioxine; 2,6-dinitrotoluene.
na(+)/PI cotransporter 1; Napi-1; renal Na(+)-dependent phosphate cotransporter 1; renal sodium-dependent phosphate transport protein 1; renal sodium-phosphate transport protein 1; sodium-dependent phosphate transport protein 1; sodium/phosphate cotransporter 1; solute carrier family 17 (organic anion transporter), member 1; solute carrier family 17 (sodium phosphate), member 1; solute carrier family 17 vesicular glutamate transporter), member 1
Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC17A1 mRNA], Allopurinol inhibits the reaction [[Oxonic Acid analog co-treated with Hypoxanthine] results in decreased expression of SLC17A1 protein]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC17A1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC17A1 mRNA more ...
[Clofibrate co-treated with Acetaminophen] affects the expression of SLC17A1 mRNA, PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of SLC17A1 mRNA]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC17A1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC17A1 mRNA more ...
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC17A1 mRNA more ...
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC17A1 mRNA more ...
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC17A1 mRNA more ...
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC17A1 mRNA
[Clofibrate co-treated with Acetaminophen] affects the expression of SLC17A1 mRNA, PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of SLC17A1 mRNA]
Expression of vesicular glutamate transporters, VGluT1 and VGluT2, in axon terminals of nociceptive primary afferent fibers in the superficial layers of the medullary and spinal dorsal horns of the rat.